Phase 2 study of the focal adhesion kinase inhibitor defactinib (VS-6063) in previously treated advanced KRAS mutant non-small cell lung cancer.

[1]  N. Pavlakis,et al.  Maintenance Defactinib Versus Placebo After First-Line Chemotherapy in Patients With Merlin-Stratified Pleural Mesothelioma: COMMAND-A Double-Blind, Randomized, Phase II Study. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  AMG 510 First to Inhibit "Undruggable" KRAS. , 2019, Cancer discovery.

[3]  P. Zarrinkar,et al.  Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor , 2018, Cell.

[4]  E. Giovannetti,et al.  Enhanced efficacy of AKT and FAK kinase combined inhibition in squamous cell lung carcinomas with stable reduction in PTEN , 2017, Oncotarget.

[5]  P. Jänne,et al.  Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  J. Morales,et al.  Focal Adhesion Kinase Regulates the DNA Damage Response and Its Inhibition Radiosensitizes Mutant KRAS Lung Cancer , 2016, Clinical Cancer Research.

[7]  Jean Mosser,et al.  Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT) , 2016, The Lancet.

[8]  C. Logothetis,et al.  Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer. , 2015, Cancer research.

[9]  Suzanne F. Jones,et al.  A phase I study of VS-6063, a second-generation focal adhesion kinase inhibitor, in patients with advanced solid tumors , 2015, Investigational New Drugs.

[10]  F. Kaye,et al.  Targeting Focal Adhesion Kinase and Resistance to mTOR Inhibition in Pancreatic Neuroendocrine Tumors. , 2015, Journal of the National Cancer Institute.

[11]  P. Jänne,et al.  Impact of KRAS codon subtypes from a randomised phase II trial of selumetinib plus docetaxel in KRAS mutant advanced non-small-cell lung cancer , 2015, British Journal of Cancer.

[12]  Michael Peyton,et al.  Co-occurring genomic alterations define major subsets of KRAS-mutant lung adenocarcinoma with distinct biology, immune profiles, and therapeutic vulnerabilities. , 2015, Cancer discovery.

[13]  D. Planchard,et al.  A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)†. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[14]  William Pao,et al.  Using multiplexed assays of oncogenic drivers in lung cancers to select targeted drugs. , 2014, JAMA.

[15]  Taebo Sim,et al.  Therapeutic targeting of oncogenic K-Ras by a covalent catalytic site inhibitor. , 2014, Angewandte Chemie.

[16]  Kevan M. Shokat,et al.  K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions , 2013, Nature.

[17]  Jie Huang,et al.  Role of focal adhesion kinase in regulating YB-1-mediated paclitaxel resistance in ovarian cancer. , 2013, Journal of the National Cancer Institute.

[18]  D. Gerber,et al.  Baseline tumour measurements predict survival in advanced non-small cell lung cancer , 2013, British Journal of Cancer.

[19]  P. Jänne,et al.  Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  G. Giaccone,et al.  Two parallel randomized phase II studies of selumetinib (S) and erlotinib (E) in advanced non-small cell lung cancer selected by KRAS mutations. , 2013 .

[21]  M. To,et al.  The genetics and biology of KRAS in lung cancer , 2013, Chinese journal of cancer.

[22]  I. Wistuba,et al.  RHOA-FAK is a required signaling axis for the maintenance of KRAS-driven lung adenocarcinomas. , 2013, Cancer discovery.

[23]  Lucio Crinò,et al.  Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. , 2013, The Lancet. Oncology.

[24]  Angela N. Brooks,et al.  Mapping the Hallmarks of Lung Adenocarcinoma with Massively Parallel Sequencing , 2012, Cell.

[25]  D. Camidge,et al.  Safety, pharmacokinetic, and pharmacodynamic phase I dose-escalation trial of PF-00562271, an inhibitor of focal adhesion kinase, in advanced solid tumors. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. Weinberg,et al.  The outgrowth of micrometastases is enabled by the formation of filopodium-like protrusions. , 2012, Cancer discovery.

[27]  John V Heymach,et al.  Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. , 2012, Journal of the National Cancer Institute.

[28]  Edward S. Kim,et al.  The BATTLE trial: personalizing therapy for lung cancer. , 2011, Cancer discovery.

[29]  Edward S. Kim,et al.  Molecular predictors of outcome with gefitinib and docetaxel in previously treated non-small-cell lung cancer: data from the randomized phase III INTEREST trial. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  M. Wicha,et al.  Mammary epithelial-specific ablation of the focal adhesion kinase suppresses mammary tumorigenesis by affecting mammary cancer stem/progenitor cells. , 2009, Cancer research.

[31]  Edward S. Kim,et al.  Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial , 2008, The Lancet.

[32]  Brian H. Dunford-Shore,et al.  Somatic mutations affect key pathways in lung adenocarcinoma , 2008, Nature.

[33]  V. Brunton,et al.  Src and focal adhesion kinase as therapeutic targets in cancer. , 2008, Current opinion in pharmacology.

[34]  D. Schlaepfer,et al.  Multiple connections link FAK to cell motility and invasion. , 2004, Current opinion in genetics & development.

[35]  P. Casey,et al.  High Affinity for Farnesyltransferase and Alternative Prenylation Contribute Individually to K-Ras4B Resistance to Farnesyltransferase Inhibitors* , 2003, Journal of Biological Chemistry.

[36]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.